Perrigo Company plc Ordinary Shares (PRGO) Company Bio
Perrigo Company develops, manufactures, and distributes generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The company was founded in 1887 and is based in Dublin, Ireland.
PRGO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for PRGO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that PERRIGO Co plc ranked in the 21th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for PRGO, they are:
The company's balance sheet shows it gets 63% of its capital from equity, and 37% of its capital from debt. Its equity weight surpasses that of only 16.2% of free cash flow generating stocks in the Healthcare sector.
Its compound free cash flow growth rate, as measured over the past 5.53 years, is -0.11% -- higher than just 12.84% of stocks in our DCF forecasting set.
PERRIGO Co plc's weighted average cost of capital (WACC) is 10%; for context, that number is higher than 70.32% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of PERRIGO Co plc? See BSX, EHC, MTD, NUVA, and CNC.
DUBLIN and GRAND RAPIDS, Mich., Jan. 11, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, announced today a formal partnership with Michigan State University (MSU), connecting the university's clinical and research…
DUBLIN--(BUSINESS WIRE)--The "Global Ibuprofen Market (by Product, Dosage Form, Process & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering. The global ibuprofen market is projected to reach US$7.54 billion in 2024, progressing at a CAGR of 2.47%, over the period 2020-2024. Companies Mentioned BASF SE IOL Chemicals & Pharmaceuticals Ltd. Perrigo Company PLC Shandong Xinhua Pharmaceutical Co., Ltd. S
DUBLIN, Dec. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that EVP and President of Consumer Self-Care Americas, Rich Sorota will present at the ICR Conference at 11:30 AM EST on Monday, January 11, 2021. Perrigo President & CEO Murray S. Kessler and…